Karyopharm Therapeutics Inc. announced that several abstracts detailing new selinexor data have been selected for presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO Annual Meeting) being held May 31 - June 4 in Chicago, IL. Details for the 2024 ASCO Annual Meeting abstracts are as follows: Abstract Title Presentation Type Abstract # Session Date/Time Endometrial Cancer Up Updates on Abstract 427956: Long-Term Rapid Oral 427956 June 1, 2024 Follow up of Selinexor Maintenance in Patients with TP53wt Advanced or Recurrent Endometrial Cancer--A Pre- Specified Subgroup Analysis from the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study (Rapid abstract update presentation 12:30pm-1:30pm CDT following July 25, 2023 Plenary Series) Phase 3 Dose Selection for Selinexor in Poster 5594 June 3, 2024TP53wt Endometrial Cancer Based on exposure-Response Analysis 9:00am - 12:00pm CDT Myelofibrosis Phase 3 Trial Design: Randomized Poster TPS6594 June 3, 2024 Double-Blind Study Evaluating Selinexor, an XPO1 inhibitor, Plus Ruxolitinib in Jaki-Naive Myelofibrosis. Phase 2 Study Trial Design: Evaluating Poster TPS6593 June 3, 2024 Selinexor Monotherapy in Patients with Jaki- Naive Myelofibrosis and Moderate Thrombocytopenia.

XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including in endometrial cancer and myelofibrosis.